These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17622114)

  • 1. Tablet formulation studies on nimesulide and meloxicam-cyclodextrin binary systems.
    Nalluri BN; Chowdary KP; Murthy KV; Becket G; Crooks PA
    AAPS PharmSciTech; 2007 May; 8(2):Article 36. PubMed ID: 17622114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tablet formulation studies on an oxcarbazepine-beta cyclodextrin binary system.
    Patel NV; Chotai NP; Patel MP
    Pharmazie; 2008 Apr; 63(4):275-81. PubMed ID: 18468386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tablet formulation containing meloxicam and beta-cyclodextrin: mechanical characterization and bioavailability evaluation.
    Ghorab MM; Abdel-Salam HM; El-Sayad MA; Mekhel MM
    AAPS PharmSciTech; 2004 Jul; 5(4):e59. PubMed ID: 15760056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation and evaluation of meloxicam oral disintegrating tablet with dissolution enhanced by combination of cyclodextrin and ion exchange resins.
    Samprasit W; Akkaramongkolporn P; Ngawhirunpat T; Rojanarata T; Opanasopit P
    Drug Dev Ind Pharm; 2015 Jun; 41(6):1006-16. PubMed ID: 24865111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and evaluation of fast-dissolving tablets of meloxicam-β-cyclodextrin complex prepared by direct compression.
    Obaidat AA; Obaidat RM
    Acta Pharm; 2011 Mar; 61(1):83-91. PubMed ID: 21406346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems.
    Naidu NB; Chowdary KP; Murthy KV; Satyanarayana V; Hayman AR; Becket G
    J Pharm Biomed Anal; 2004 Apr; 35(1):75-86. PubMed ID: 15030882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and evaluation of an orally fast disintegrating tablet formulation containing a hydrophobic drug.
    Comoglu T; Unal B
    Pharm Dev Technol; 2015 Jan; 20(1):60-4. PubMed ID: 24295202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meloxicam β-cyclodextrin transdermal gel: physicochemical characterization and in vitro dissolution and diffusion studies.
    Rasool BK; Gareeb RH; Fahmy SA; Rasool AA
    Curr Drug Deliv; 2011 Jul; 8(4):381-91. PubMed ID: 21453259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Application of β-cyclodextrin in the formulation of ODT tablets containing ibuprofen].
    Zimmer Ł; Kasperek R; Poleszak E
    Polim Med; 2014; 44(4):231-5. PubMed ID: 25932904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
    Badr-Eldin SM; Elkheshen SA; Ghorab MM
    Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An optimized commercially feasible milling technique for molecular encapsulation of meloxicam in β-cyclodextrin.
    Bandarkar FS; Vavia PR
    Drug Dev Ind Pharm; 2011 Nov; 37(11):1318-28. PubMed ID: 21506882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and optimization of a meloxicam/β-cyclodextrin complex for orally disintegrating tablet using statistical analysis.
    Ainurofiq A; Choiri S
    Pharm Dev Technol; 2018 Jun; 23(5):464-475. PubMed ID: 27875913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of fast-dissolving tablets of flurbiprofen-cyclodextrin complexes.
    Cirri M; Rangoni C; Maestrelli F; Corti G; Mura P
    Drug Dev Ind Pharm; 2005 Aug; 31(7):697-707. PubMed ID: 16207617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of ternary complexes of meloxicam-HPbetaCD and PVP or L-arginine prepared by the spray-drying technique.
    El-Maradny HA; Mortada SA; Kamel OA; Hikal AH
    Acta Pharm; 2008 Dec; 58(4):455-66. PubMed ID: 19103579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of meloxicam formulations utilizing ternary complexation for solubility enhancement.
    Awasthi SS; Kumar TG; Manisha P; Preeti Y; Kumar SS
    Pak J Pharm Sci; 2011 Oct; 24(4):533-8. PubMed ID: 21959817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nimesulide and beta-cyclodextrin inclusion complexes: physicochemical characterization and dissolution rate studies.
    Chowdary KP; Nalluri BN
    Drug Dev Ind Pharm; 2000 Nov; 26(11):1217-20. PubMed ID: 11068697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of inclusion complexation of meloxicam with β-cyclodextrin- and β-cyclodextrin-based nanosponges on solubility, in vitro release and stability studies.
    Shende PK; Gaud RS; Bakal R; Patil D
    Colloids Surf B Biointerfaces; 2015 Dec; 136():105-10. PubMed ID: 26364091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo evaluation of oral tablet formulations prepared with ketoconazole and hydroxypropyl-beta-cyclodextrin.
    Taneri F; Ozcan I; Guneri T
    Drug Deliv; 2010 Apr; 17(3):152-7. PubMed ID: 20148713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation development of intermediate release Nimesulide tablets by CCRD for IVIVC studies.
    Hanif M; Shoaib MH; Yousuf RI; Sattar S; Nadeem M; Hussain L; MZia MU; Muhammad IN; Uzair M; Qadir I
    Pak J Pharm Sci; 2014 Jul; 27(4):785-92. PubMed ID: 25015441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elastic liposomes bearing meloxicam-beta-cyclodextrin for transdermal delivery.
    Jain SK; Gupta Y; Jain A; Amin S
    Curr Drug Deliv; 2008 Jul; 5(3):207-14. PubMed ID: 18673264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.